Menu
Search
|

Menu

Close
X

Akebia Therapeutics Inc AKBA.OQ (NASDAQ Stock Exchange Global Market)

8.30 USD
-- (--)
As of Oct 22
chart
Previous Close 8.30
Open --
Volume --
3m Avg Volume 171,357
Today’s High --
Today’s Low --
52 Week High 18.27
52 Week Low 7.34
Shares Outstanding (mil) 47.15
Market Capitalization (mil) 894.46
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.12 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
95
FY17
178
FY16
2
FY15
0
EPS (USD)
FY18
-1.081
FY17
-1.910
FY16
-3.593
FY15
-2.266
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
17.57
5.83
Price to Book (MRQ)
vs sector
14.14
4.89
Price to Cash Flow (TTM)
vs sector
--
22.92
Total Debt to Equity (MRQ)
vs sector
0.00
17.21
LT Debt to Equity (MRQ)
vs sector
0.00
12.79
Return on Investment (TTM)
vs sector
-85.01
14.27
Return on Equity (TTM)
vs sector
-147.39
15.99

EXECUTIVE LEADERSHIP

Muneer Satter
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
John Butler
President, Chief Executive Officer, Director, Since 2013
Salary: $542,769.00
Bonus: --
Jason Amello
Chief Financial Officer, Senior Vice President, Treasurer, Since 2013
Salary: $344,448.00
Bonus: $131,579.00
Nicole Hadas
Senior Vice President, General Counsel, Secretary, Since 2013
Salary: --
Bonus: --
Michel Dahan
Senior Vice President and Chief Business Officer, Since 2013
Salary: $315,097.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

245 1st St
CAMBRIDGE   MA   02142-1200

Phone: +1617.8712098
Site: akebia.com/

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

SPONSORED STORIES